Reported fiscal results for the fourth quarter and year ended March 31, 2023. The Company recognized a net loss from discontinued operations of $10.4 million for the 12-month period ended March 31, 2023. No such loss was incurred during the three-month period ended March 31, 2023. This compares to a $8.2 and $36.9 million loss for the three- and 12-month periods ended March 31, 2022. Discontinued operations are attributable to the spinout of Clinic Operations completed on August 11, 2022. Reunion Neuroscience Inc. shares T.REUN are trading unchanged at $1.45.
Stocks in play: Reunion Neuroscience Inc.
Baystreet - Contributor Content 
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
/NVIDIA%20Corp%20logo%20on%20phone-by%20Evolf%20via%20Shutterstock.jpg)
/Micron%20Technology%20Inc_%20logo%20on%20building-by%20vzphotos%20vis%20iStock.jpg)
/A%20Palantir%20office%20building%20in%20Tokyo_%20Image%20by%20Hiroshi-Mori-Stock%20via%20Shutterstock_.jpg)
/Semiconductor%20chip%20by%20Mykola%20Pokhodzhay%20via%20iStock.jpg)
